


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/509,277
				Filing Date	September 27, 2004
				First Named Inventor	W.K. Hagmann et al.
				Group Art Unit	1621
				Examiner Name	S. Kumar
Sheet	1	of	4	Attorney Docket Number	21071YP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
S		5624941		Barth et al.	04/29/1997
		6028084		Barth et al.	02/22/2000
		5013837		Ward et al.	05/07/1991
		4973587		Ward et al.	11/27/1990
		5081122		Ward	01/14/1992
		5112820		Ward	05/12/1992
		5292736		Kumar et al.	03/08/1994
		6344474		Maruani et al.	02/05/2002
		USSN 60/515,705		Shah et al.	
		USSN 60/504,377		Armstrong et al.	
		USSN 10/507,864		Hagmann et al.	
		US2004-0058820		Hagmann et al.	03/25/2004
		USSN 60/483,679		Burns et al.	
		5658943		Berryman et al.	08/19/1997

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
			EP 658546		Sanofi-Synthelabo	05/23/2001
			WO 98/31227		SmithKline Beecham Corporation	07/23/1998
			WO 98/41519		SmithKline Beecham Corporation	09/24/1998
			WO 98/37061		Bayer Aktiengesellschaft	08/27/1998
			WO 00/10967		Bayer Aktiengesellschaft	03/02/2000
			WO 00/10968		Bayer Aktiengesellschaft	03/02/2000
			WO 97/29079		Japan Tobacco Inc.	08/14/1997
			WO 02/076945		Ortho-MacNeil Pharmaceutical, Inc.	10/03/2002
			WO 03/077847		Merck & Co., Inc.	09/25/2003
			WO 03/086288		Merck & Co., Inc.	10/23/2003

Examiner Signature	S. Kumar	Date Considered	9/13/04
--------------------	----------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/509,277
Filing Date	September 27, 2004
First Named Inventor	W.K. Hagmann et al.
Group Art Unit	1621
Examiner Name	S. Ku

Sheet	2	of	4	Attorney Docket Number	21071YP
-------	---	----	---	------------------------	---------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
g			WO 03/082256	Sanofi-Synthelabo	10/09/2003
			WO 01/58450	Sanofi-Synthelabo	08/16/2001
			WO 01/85092	Sanofi-Synthelabo	11/15/2001
			EP 1328269	Aventis Pharma S.A.	05/26/2004
			WO 04/040040	UHDE GMBH	05/13/2004
			FR 1358M	L'Equilibre Biologique	06/18/2002
			WO 00/25774	Merck & Co., Inc.	05/01/2000
			GB 1172346	Parke, Davis & Company	11/26/1969
			GB 899556	Farbwerke Hoeschst Aktiengesellschaft	06/27/1962
			WO 97/27852	Merck & Co., Inc.	08/07/1997

**Examiner
Signature**

S. Kumar

Date Considered

9 | 13 | 05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

STATEMENT BY APPLICANT

COMPLETE IF KNOWN

Application Number	10/507,864
Filing Date	September 16, 2004
First Named Inventor	W.K. Hagmann et al.
Group Art Unit	1621
Examiner Name	S. Kuv

Sheet	3	of	4	Attorney Docket Number	21071YP
-------	---	----	---	------------------------	---------

[illegible][illegible]

**Examiner
Signature**

S. Kumar

Date Considered

$$9 \mid 13 \mid 0.5$$

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/509,277
				Filing Date	September 27, 2004
				First Named Inventor	W.K. Hagmann et al.
				Group Art Unit	1621
				Examiner Name	S. Kumar
Sheet	4	of	4	Attorney Docket Number	21071YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
SA	AA	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
	AB	Xiang et al., Ann. Rep. Med. Chem., A. Doherty, ed., Academic Press, NY (1999), Vol. 34, pp. 199-208, "Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists"
	AC	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
	AD	Piomelli et al., Trends in Pharm. Sci., Vol. 21 (2000), pp. 218-224, "The endocannabinoid system as a target for therapeutic drugs"
	AE	Lack et al., J. Pharmacol. Expt'l. Therap., Vol. 139 (1963), pp. 248-258, "The intestinal action of benzmalecene: The Relationship of its hypocholesterolemic effect to active transport of bile salts and other substances"
	AF	Julian et al., Eur. J. Org. Chem. (2000), pp. 1319-1325, "Asymmetric synthesis of 2,4-disubstituted tetrahydroquinolines"
✓	AG	Lette et al., Ann., Vol. 603 (1957), pp. 189-99, "Uber benzhydrylalkylamine. Ein beitrag zur analyse der mitosehemmenden wirkung des colchicins"

Examiner Signature	S. Kumar	Date Considered	9/13/05
--------------------	----------	-----------------	---------